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Aims To evaluate the diagnostic accuracy of a combined non-invasive assessment of coronary artery disease with coronary
CT angiography (CTA) and myocardial perfusion imaging (MPI) for the detection of flow-limiting coronary stenoses
and its potential as a gatekeeper for invasive examination and treatment.
Methods
and results
In 78 patients (mean age 65+ 9 years) referred for coronary angiography (CA), additional CTA and MPI (using single-
photon emission-computed tomography) were performed and the findings not communicated. Detection of flow-
limiting stenoses ( justifying revascularization) by the combination of CTA and MPI (CTA/MPI) was compared with
the combination of quantitative coronary angiography (QCA) plus MPI (QCA/MPI), which served as standard of
reference. The findings of both combinations were related to the treatment strategy (revascularization vs. medical
treatment) chosen in the catheterization laboratory based on the CA findings. Sensitivity, specificity, positive and
negative predictive value, and accuracy of CTA/MPI for the detection of flow-limiting coronary stenoses were
100% each. More than half of revascularization procedures (21/40, 53%) was performed in patients without flow-lim-
iting stenoses and 76% (47/62) of revascularized vessels were not associated with ischaemia on MPI.
Conclusion The combined non-invasive approach CTA/MPI has an excellent accuracy to detect flow-limiting coronary stenoses
compared with QCA/MPI and its use as a gatekeeper appears to make a substantial part of revascularization pro-
cedures redundant.
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Introduction
Over the past decades, many advances in imaging techniques have
enhanced our pathophysiologic understanding of coronary artery
disease (CAD). A comprehensive assessment of CAD should
include both information on coronary artery anatomy and func-
tional information about the haemodynamic relevance of coronary
artery lesions in order to guide revascularization procedures.1–3
In stable CAD, the debate on the role of elective percutaneous
coronary intervention (PCI) is highly controversial.4,5 Guidelines
recommend proof of ischaemia prior to elective revascularization
of coronary stenoses,2,4,6 and several reports have demonstrated
that PCI fails to improve prognosis in patients with stable CAD
compared with conservative treatment.5,7 Nonetheless, in clinical
practice, the decision to revascularize is often based solely upon
visual angiographic criteria rather than objective proof of
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ischaemia. Similarly, while quantitative coronary angiography
(QCA) is commonly used as gold standard in clinical trials,8 its
clinical role is limited as accurate analysis is generally not readily
available during the procedure.
Coronary multislice CT angiography (CTA) has evolved rapidly
during the past decade allowing now visualization of coronary
artery morphology and lesions with a temporal and spatial resol-
ution that approaches conventional coronary angiography
(CA).9,10 Combination of CTA and myocardial perfusion imaging
(MPI) is non-invasive, and thus, allow non-invasive integrative
assessment of CAD.11 Hence, it seems conceivable that an early
non-invasive assessment of CAD with CTA and SPECT may act
as a gatekeeper for conventional coronary angiography and
thus avoid unnecessary invasive diagnostic and revascularization
procedures.
Therefore, the aim of the present study was to evaluate the diag-
nostic accuracy of the combination CTA/MPI vs. QCA/MPI as a
gatekeeper for invasive coronary examination and treatment.
Methods
Study population and study design
We prospectively enrolled consecutive patients with known or sus-
pected CAD referred to our institution for elective CA. The clinical
decision to perform CA was based on the history and/or symptoms
of the patient and/or on the results from exercise stress testing.
Patients were eligible if they were in a stable clinical condition i.e. if
they were in Canadian Cardiac Society class I to III, and in
New York Heart Association functional class I to III. Exclusion criteria
were severe obstructive lung disease, high-grade atrioventricular con-
duction disturbances, atrial fibrillation, and known intolerance of iodi-
nated contrast agents. Patients who agreed to participate underwent
CTA and myocardial perfusion SPECT prior to the invasive procedure
and the results from non-invasive testing were withheld from the inter-
ventional cardiologist. The study protocol was approved by the local
institutional review board and all patients gave written informed
consent before enrolment. All patients were made aware of the
additional radiation dose from MPI and CTA prior to consent. The
study population is shared with a prior publication by our group.12
CT angiography image acquisition
All scans were performed on a 64-slice CT scanner (Somatom Sen-
sation 64; Siemens Medical Solutions, Forchheim, Germany). Patients
with pre-scan heart rates above 70 b.p.m. received intravenous beta-
blocker therapy (5–15 mg metoprolol) immediately prior to the CT
scan. Low-dose calcium score, helical CTA scanning, and image recon-
struction parameters were used as previously reported.12,13
CT angiography image interpretation
CT angiography image interpretation was performed on axial source
images, multiplanar and curved reformations, and thin-slab maximum
intensity projections. First, image quality for each data set was rated
by one reader on a scale ranging from score 1 (excellent image
quality), 2 (good image quality), 3 (moderate image quality), 4 (poor,
but still diagnostic image quality), to score 5 (very poor image
quality, non-evaluable data set defined as having at least one
non-evaluable segment). Coronary arteries were subdivided according
to a 15-segment model proposed by the American Heart
Association.14
Then, each segment was visually evaluated on at least two planes,
one parallel and one perpendicular to the course of the vessel with
regard to coronary artery delineation. On these images, the degree
of diameter stenosis was qualitatively graded by two independent
readers (who were both blinded to the clinical history and to the find-
ings from MPI and CA) on a decimal scale in 10% steps from 0 to 100%.
The ultimate diameter stenosis was calculated as the mean of both
measurements. A significant stenosis was defined as narrowing of
the coronary lumen 50%, and all vessels with a diameter down to
1.5 mm were included in the analysis.
Myocardial perfusion imaging image
acquisition
SPECT image acquisition was performed using a 1 day electrocardio-
graphically (ECG) gated stress/rest protocol with adenosine stress
(140 mg/kg/min) and 99mTc-tetrofosmin (250–350 MBq at peak
stress and three times the stress dose at rest according to standard
protocol).15 Scanning parameters and image reconstruction algorithms
were applied as previously reported.12 Patients were told to refrain
from caffeine-containing beverages for at least 12 h, nitrates and
calcium channel blockers 24 h, and beta-blockers 48 h before the
MPI study.
Myocardial perfusion imaging image
interpretation
SPECT image interpretation was visually performed by consensus of
two experienced nuclear cardiologists on short axis, horizontal long
axis, and vertical long-axis slices, and semiquantitative polar maps of
perfusion using previously validated automated software.16 Anterior
and septal wall perfusion defects were allocated to the left anterior
descending (LAD) coronary artery, lateral defects to the left circum-
flex (LCX) coronary artery, and inferior defects to the right coronary
artery (RCA). Reversible perfusion defects were considered to rep-
resent myocardial ischaemia. Fixed perfusion defects with concomitant
regional wall motion abnormalities were considered to be myocardial
scars.17
Quantitative coronary angiography
Biplane conventional CA was performed according to standard tech-
niques and evaluated by an experienced observer who was blinded
to the results from CTA and MPI. Quantitative coronary angiography
measurements were performed on two different image planes using
an automated edge-detection system (Xcelera 1.2, Philips Medical
Systems, Best, The Netherlands) as previously described.12 A signifi-
cant stenosis was defined as a diameter reduction of 50%.
Comparison of CT angiography and
quantitative coronary angiography
The diagnostic accuracy of CTA was assessed by comparison with the
results from QCA, which was considered to be the gold standard for
coronary stenosis evaluation. Comparison was performed on an
intention-to-diagnose basis and therefore, non-evaluable segments
on CTA were considered as positives.
Assessment of flow-limiting coronary
stenoses
A flow-limiting coronary stenosis was defined as a lesion with a diam-
eter narrowing exceeding 50% (on CTA or on QCA) inducing a
reversible perfusion defect in its subtending myocardial territory on
MPI (myocardial ischaemia) (Figure 1). A coronary stenosis of 50%
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without any associated myocardial ischaemia was considered to be
non-flow-limiting. Conversely, a reversible perfusion defect in a terri-
tory subtended by a non-stenotic coronary artery was considered to
represent a false-positive MPI result. As shown in Figure 1, the presence
or absence of flow-limiting coronary stenosis was assessed indepen-
dently for the combination of CTA plus MPI (CTA/MPI) and for the
combination of QCA plus MPI (QCA/MPI), the latter being considered
the gold standard for a combined assessment of coronary morphology
and haemodynamic lesion severity.
Coronary revascularizations
Coronary revascularization procedures included PCI with or without
stent implantation and coronary artery bypass grafting (CABG).
According to guidelines, a stenosis was considered as an indication
for revascularization only if it was associated with a reversible per-
fusion defect on MPI (flow-limiting stenosis). Finally, the patients’
actual treatment strategy (revascularization vs. medical treatment)
was compared with the imaging-derived treatment recommendations,
on patient- and vessel-based analysis.
Statistical analysis
Statistical analysis was performed using the SPSS software package
(SPSS 12.0.1 for Windows, SPSS Corp.). Quantitative data are
expressed as mean+ SD (unless otherwise stated) and categorical
data given in proportions and percentages. Statistical comparison of
quantitative data was performed using an unpaired two-tailed Student’s
t-test or Mann–Whitey U test where appropriate and comparison of
categorical data using a chi-squared test with Yates’ correction or
McNemar’s test for comparison of paired proportions. A P-value
,0.05 was considered statistically significant for all tests. Pre-test
CAD likelihood was calculated according to Diamond and Forrester.18
Sensitivity, specificity, positive (PPV), and negative predictive value
(NPV), and accuracy were obtained from 22 contingency tables
and their respective 95% confidence intervals (CIs) calculated from
binomial expression. Accuracy was determined as the percentage of
correct diagnoses in the entire sample. Univariate logistic regression
was used to identify predictors for revascularization and the regression
results are presented as odds ratios and their respective 95% CIs.
Additionally, multivariate logistic regression was applied to identify
independent predictors by including all factors with P, 0.05 and cor-
rection for the baseline characteristics with P, 0.1 on univariate
analysis.
Results
Ninety-six patients were enrolled in the study, of which 18 (19%)
had to be excluded: no CTA (n ¼ 7) due to atrial fibrillation or
technical reasons, no CA (n ¼ 11) due to rescheduling, consent
withdrawal, clinical deterioration, and logistic reasons. The final
analysis included 78 patients with a mean age of 65+ 9 years
(range, 40–87 years) [35 (45%) female] (Table 1). The median
time interval between CTA and MPI was 0 days (range, 0 to 26
days), between CTA and CA 1 day (range, 0 to 22 days), and
between MPI and CA 1 day (range, 0 to 26 days). A delay of
more than 2 weeks between CTA and MPI was found in only
one patient, and between CTA/MPI and CA in five patients.
CT angiography results
All patients were in stable sinus rhythm and the mean heart rate
during the CT scan was 62+9 b.p.m. Ten patients (13%) were
pre-treated with intravenous metoprolol.
A total number of 1093 coronary segments in 310 main coron-
ary arteries were analysed. In two patients, the left main coronary
artery (LMA) was missing as LAD and LCX had separate origins
from the left coronary sinus. The mean image quality score was
2.9+ 0.9. Image quality scores were 1 in 1 (1%) patient, 2 in 31
(40%) patients, 3 in 26 (33%) patients, 4 in 15 (19%) patients,
and 5 in 5 (6%) patients. Eight (1%) coronary segments were not
evaluable because of motion artefacts (n ¼ 2), heavy calcifications
(n ¼ 1), or both (n ¼ 5). On intention-to-diagnose basis, visual
CTA image analysis revealed a stenosis in 137/1093 (13%) seg-
ments corresponding to 91/310 (29%) coronary arteries in 46/78
(59%) patients (Figure 2). The details of the CTA results are
given in Table 2. Interreader agreement for stenosis detection on
CTA was 92% (95% CI, 90–93%) on segment-based analysis.
Myocardial perfusion imaging results
Image quality of MPI was amenable to visual interpretation in all
78 patients. Visual image analysis revealed 14 reversible, 13 fixed,
and 6 partially reversible perfusion defects in 31/78 (40%) patients
(Table 2). The distribution of the perfusion defects among the
different coronary artery territories was as follows: reversible
perfusion defects: LAD (n ¼ 8), LCX (n ¼ 2), RCA (n ¼ 4); fixed
perfusion defects: LAD (n ¼ 4), LCX (n ¼ 3), RCA (n ¼ 6);
partially reversible perfusion defects: LAD (n ¼ 1), LCX (n ¼ 1),
RCA (n ¼ 4).
Coronary angiography results
Quantitative coronary angiography analysis of biplane CA revealed
stenoses (of 50% diameter stenosis) in 92/310 (30%) coronary
arteries corresponding to 49/78 (63%) patients. As with CTA,
the LMA was missing in two patients as LAD and LCX had separate
Figure 1 Diagnostic and treatment algorithm. A flow-limiting
coronary stenosis (third row) was defined in the presence of
angiographically significant stenoses (first row) and evidence of
ischaemia on myocardial perfusion imaging (second row). Only
flow-limiting coronary stenoses were considered as an indication
for revascularization (fourth row).
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origins from the left coronary sinus. The details of the QCA results
are given in Table 2.
Comparison of CT angiography vs.
quantitative coronary angiography
Sensitivity, specificity, PPV, NPV, and accuracy of CTA for the
detection of coronary stenoses on QCA was 88% (95% CI,
80–94%), 95% (92–98%), 89% (81–95%), 95% (91–97%),
and 93% (90–96%), respectively, on vessel-based analysis, and
94% (83–99%), 100% (88–100%), 100% (92–100%), 91%
(75–98%), and 96% (89–99%), respectively, on patient-based
analysis.
Assessment of flow-limiting stenoses
On both combined analyses of CTA/MPI as well as QCA/MPI 19/78
(24%) patients had flow-limiting stenoses. Eight stenoses were loca-
lized in the LAD-, 2 in the LCX-, and 9 in the RCA-territory. Sensi-
tivity, specificity, PPV, NPV, and accuracy of the combination CTA/
MPI for the detection of flow-limiting coronary stenoses on QCA/
MPI was 100% (95% CI, 82–100%), 100% (99–100%), 100%
(82–100%), 100% (99–100%), and 100% (99–100%), respectively,
on vessel-based analysis, and 100% (82–100%), 100% (94–100%),
100% (82–100%), 100% (94–100%), and 100% (95–100%), respect-
ively, on patient-based analysis. When including fixed perfusion
defects into the analysis, the PPV of MPI was 85% with a clear
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Table 1 Patient characteristics
All patients (n5 78) Revasc group (n5 40) Medical group (n5 38) P-value*
Age (years) 65+9 66+8 63+10 0.18
Female gender, n (%) 35 (45) 13 (33) 22 (58) 0.02
Body mass index (kg/m2) 26+4 27+4 26+4 0.37
Systolic blood pressure (mmHg) 134+19 135+19 132+19 0.47
Diastolic blood pressure (mmHg) 78+12 77+11 80+12 0.35
Total serum cholesterol (mmol/L) 4.8+1.0 4.7+0.9 4.9+1.1 0.32
Cardiovascular history, n (%)
Known CAD 19 (24) 14 (35) 5 (13) 0.02
Single-vessel CAD 5 (6) 3 (8) 2 (5) 0.69
Two-vessel CAD 5 (6) 4 (10) 1 (3) 0.39
Three-vessel CAD 9 (12) 7 (18) 2 (5) 0.18
Previous MI/ACS 16 (21) 11 (28) 5 (13) 0.20
Previous PCI 19 (24) 14 (35) 5 (13) 0.05
Previous CABG 0 (0) 0 (0) 0 (0) –
Missing exercise test 34 (44) 19 (48) 15 (39) 0.63
Pathological exercise test 35 (45) 16 (40) 19 (50) 0.51
LVEF (%) 59+15 60+11 59+18 0.94
Symptoms, n (%)
Angina pectoris CCS I-III 30 (38) 21 (53) 9 (24) 0.02
Atypical chest pain 16 (20) 5 (13) 11 (29) 0.13
Dyspnoea NYHA I–III 19 (24) 7 (18) 12 (32) 0.24
None 13 (17) 7 (18) 6 (16) .0.99
Cardiovascular risk factors, n (%)
Diabetes mellitus 13 (17) 11 (28) 2 (5) 0.02
Hypertension 61 (78) 34 (85) 27 (71) 0.22
Dyslipidaemia 40 (51) 24 (60) 16 (42) 0.18
Current or former smokers 40 (51) 25 (63) 15 (39) 0.07
Unknown CAD 59 (76) 26 (65) 33 (87) 0.03
CAD pre-test likelihood (%)a 75+26 86+16 66+30 ,0.01
Framingham risk score 12+9 15+9 10+7 0.01
Data not given in n (%) is shown as mean+ SD.
Revasc group, group of patients undergoing coronary revascularization; Medical group, group of patients treated conservatively; CAD, coronary artery disease; MI, myocardial
infarction; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction as assessed
with gated SPECT; CCS, Canadian cardiac society; NYHA, New York Heart Association.
aPre-test likelihood for CAD was calculated according to Diamond and Forrester.18
*P-value for comparison of Revasc vs. Medical group.
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trend towards improvement after addition of CTA (96%) although
the difference fell short of statistical significance (P ¼ 0.07).
Revascularizations
A revascularization procedure was performed in 40/78 (51%)
patients of whom 11/78 (14%) underwent CABG and 29/78
(37%) PCI (with stenting in all but one patients). The median
time interval between CA and revascularization procedure was
0 days (range, 0–51 days), all PCI procedures were performed
ad hoc. On vessel-based analysis, 62/310 (20%) coronary arteries
were revascularized (LMA, n ¼ 2; LAD, n ¼ 23; LCX, n ¼ 21;
RCA, n ¼ 16).
Figure 3 shows the study population subcategorized according to
the presence or absence of flow-limiting stenoses on CTA/MPI or
QCA/MPI and the treatment strategy (revascularization vs. medical
treatment) on patient- and vessel-based analysis. Typical angina
was present in 21 (53%) and 9 (24%) patients (P ¼ 0.02) in the
revascularization and medical group, respectively, and a pathologi-
cal exercise test in 16 (40%) and 19 (50%) patients, respectively
(P ¼ 0.51). However, an exercise test was only performed in 44
(56%) of patients. Among the 21 patients without flow-limiting ste-
noses undergoing revascularization, the prevalence of symptoms
was: typical angina, 25% (10/21); atypical chest pain, 5% (2/21); dys-
pnoea, 10% (4/21); and no symptoms, 13% (5/21) (P¼NS com-
pared with patients without flow-limiting stenoses and medical
treatment).
All patients with flow-limiting stenoses were revascularized.
However, more than half of revascularization procedures (21/40,
53%) were performed in patients without flow-limiting stenoses
and 76% (47/62) of revascularized vessels were not associated
with ischaemia on MPI (Figure 4). Nineteen per cent (4/21) of
revascularization procedures in patients without flow-limiting
stenoses were CABG and 81% (17/21) ad hoc PCIs. The fraction
of CABG among patients without flow-limiting stenoses tended
to be lower than in patients with flow-limiting stenoses (19 vs.
37%, P¼NS). In patients with no flow-limiting stenoses, there
were no differences in baseline characteristics between those
undergoing revascularization (n ¼ 21) and those treated medically
(n ¼ 38) except for a higher prevalence of known CAD in the
former group (62 vs. 13%, P, 0.001).
Significant clinical predictors of revascularization by univariate
logistic regression were a history of CAD, the presence of
typical angina, history of diabetes mellitus, and current or former
smoking status (Table 3). Multivariate logistic regression analysis
identified a history of diabetes mellitus as the only independent
predictor of revascularization.
Discussion
Our study documents an excellent ability of a combined non-
invasive approach with CTA and MPI using SPECT for detecting
flow-limiting coronary stenoses compared with the gold standard
of QCA combined with MPI. In all patients with flow-limiting cor-
onary stenoses (i.e. stenoses that were associated with myocardial
ischaemia as evidenced by MPI), a revascularization procedure was
performed. However, half of patients undergoing revascularization
lacked any flow-limiting coronary stenoses based on non-invasive
imaging and almost three quarters of revascularized vessels were
Figure 2 Myocardial perfusion SPECT after pharmacological stress (A) and at rest (B) showing a reversible anterior perfusion defect (ischae-
mia). The CT angiography multiplanar reconstruction of the left anterior descending artery (LAD) (C) shows three serial stenoses (arrows)
confirmed by conventional coronary angiography (D, arrows). (E) Three-dimensional SPECT/CT fusion images visualize matching of LAD ste-
noses (arrows) and anterior ischaemia.
Coronary CTA and MPI to detect flow-limiting stenoses 2925
not associated with myocardial ischaemia. These findings underline
a potential role of a combined non-invasive assessment with CTA
and MPI as a gatekeeper for revascularization procedures in order
to avoid its overuse and the associated burden of periprocedural
morbidity. By doing so, in our study population in 21/78 (27%)
patients, an unnecessary revascularization procedure might have
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Table 2 Imaging results
All patients (n5 78) Revasc group (n5 40) Medical group (n 5 38) P-value*
CTA results
Coronary calcium score (ASE)a 370 (100, 915) 529 (193, 1432) 156 (1, 586) 0.001
Patients with CTA stenoses, n (%) 46 (59) 39 (98) 7 (18) ,0.001
LMA stenoses 0 (0) 0 (0) 0 (0) –
LAD stenoses 33 (42) 30 (75) 3 (8) ,0.001
LCX stenoses 28 (36) 25 (63) 3 (8) ,0.001
RCA stenoses 30 (38) 26 (65) 4 (11) ,0.001
MPI results
Fixed perfusion defects 13 (17) 9 (23) 4 (11) 0.27
Reversible and partially reversible perfusion defects 20 (26) 20 (50) 0 (0) ,0.001
Normal MPI perfusion 47 (60) 13 (33) 34 (89) ,0.001
QCA results
Patients with QCA stenoses, n (%) 49 (63) 40 (100) 9 (24) ,0.001
LMA stenoses 1 (1) 1 (3) 0 (0) 0.33
LAD stenoses 33 (42) 27 (68) 6 (16) ,0.001
LCX stenoses 29 (37) 28 (70) 1 (3) ,0.001
RCA stenoses 29 (37) 26 (65) 3 (8) ,0.001
Combination CTA/MPI: flow-limiting stenoses 19 (24) 19 (48) 0 (0) ,0.001
Combination QCA/MPI: flow-limiting stenoses 19 (24) 19 (48) 0 (0) ,0.001
Revasc group, group of patients undergoing coronary revascularization; Medical group, group of patients treated conservatively; CTA, CT angiography; ASE, Agatston score
equivalents; LMA, left main artery; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; MPI, myocardial perfusion imaging; QCA,
quantitative coronary angiography.
aData for coronary calcium score are given as median and interquartile range and comparison performed using Mann–Whitney U test.
*P-value for comparison of Revasc vs. Medical group.
Figure 3 Classification of patients (A. patient-based analysis) and coronary arteries (B. vessel-based analysis) according to the presence or
absence of flow-limiting stenoses on the combination of CTA and MPI (CTA/MPI, empty bars) or QCA and MPI (QCA/MPI, filled bars) and
the treatment strategy (Revasc, coronary revascularization; Medical, conservative treatment).
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been prevented, while in none of the patients a revascularization
procedure would have been falsely withheld.
The role of revascularization procedures in patients with stable
CAD is controversial. As with medical therapy, the objectives of
coronary revascularization procedures are two-fold, to improve
survival free of ischaemic events, and to diminish or eradicate
ischaemic symptoms.4 Since the highest risk patients derive the
highest benefit from revascularization procedures, both the indi-
vidual risk of the patient as well as his symptomatic status must
be a major determinant in the decision-making process. High risk
factors include high risk angiographical configuration (LMA
disease, proximal three-vessel disease), impaired left ventricular
function, pronounced symptoms (angina CCS III– IV), or the pres-
ence of myocardial ischaemia by non-invasive testing.19 Coronary
revascularization procedures have convincingly shown to reduce
ischaemic symptoms and improve quality of life even in patients at
low risk.7 However, periprocedural morbidity and mortality
remain important considerations. In fact, in a stable CAD popu-
lation, coronary revascularization procedures have failed to demon-
strate an improvement in prognosis compared with state-of-the-art
medical therapy.5,7,19,20 Therefore, guidelines recommend proof of
ischaemia prior to revascularization procedures.2,4 If moderate to
large ischaemia is present, however, a coronary revascularization
may actually improve prognosis compared with medical treatment21
by a more effective reduction in the amount of jeopardized myocar-
dium.22 On the other hand, revascularization of a non-flow-limiting
coronary stenosis is not of benefit for the patient, neither from a
prognostic nor from a symptomatic point of view.23,24
Therefore, MPI has been suggested as gatekeeper for invasive
examination.25 However, combining MPI with CTA has been
shown to improve the accuracy of non-invasive assessment,26 as
false positive MPI findings may be disproved by negative CTA
which may be of particular importance in low CAD prevalence
populations. In addition, not every flow-limiting lesion may be
suitable for PCI, which may be identified by CTA avoiding futile
invasive attempts. Interestingly, only 56% of patients in our non-
selected study population had undergone a stress ECG prior to
CA, and in less than half of patients the stress ECG was pathologic.
However, patients in the revascularization group had a higher
prevalence of angina pectoris. This may explain why a considerable
amount of presumably non-flow-limiting lesions were nevertheless
revascularized, as 87% of these patients had symptoms. This
reflects that in clinical reality, a decision to revascularize often
also incorporates the overall presentation and symptoms of a
patient. Of note, the vast majority of these revascularization pro-
cedures were ad hoc PCIs. This observation is in line with previous
publications reporting that 66% of PCIs are ad hoc procedures in
stable CAD patients.27
Several factors may contribute to the observed discrepancy
between guidelines and the use of PCI in real life, among them
insufficient use of non-invasive testing, and potential medicolegal
considerations (presumably not allowing a detected stenosis
untreated). The latter may be driven by the open artery theory,
although not supported by the latest results.28 In fact, previous
reports have documented a high correlation between catheteriza-
tion and revascularization rates.29 Our results suggest the use of a
combined non-invasive approach with CTA and MPI prior to
Figure 4 Example of a patient with non-flow-limiting stenoses
undergoing revascularization. (A) Myocardial perfusion SPECT
shows no significant perfusion defects during vasodilator stress
or at rest. (B) The 3D SPECT/CT fusion images depict stenoses
in the proximal, mid, and distal left anterior descending artery
(LAD) (arrows). Invasive coronary angiography prior (C) and
after PCI (D) document stenting of the mid and distal LAD
lesions (arrows). The proximal LAD lesion was left untreated.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Univariate predictors of revascularization
OR (95% CI) P-value*
Clinical characteristics
Age (years) 1.04 (0.98–1.09) 0.18
History of CAD 3.55 (1.13–11.15) 0.03
Previous MI/ACS 2.50 (0.78–8.06) 0.12
Pathological exercise test 0.67 (0.27–1.64) 0.38
LVEF (%) 1.00 (0.97–1.03) 0.94
Symptoms
Angina pectoris CCS I–III 3.56 (1.35–9.41) 0.01
Atypical chest pain 0.35 (0.11–1.13) 0.08
Dyspnoea NYHA I–III 0.46 (0.16–1.33) 0.15
None 1.13 (0.34–3.73) 0.84
Cardiovascular risk factors
Diabetes mellitus 6.83 (1.40–33.28) 0.02
Hypertension 2.31 (0.76–7.05) 0.14
Dyslipidaemia 2.06 (0.84–5.09) 0.12
Current or former smoker 2.56 (1.03–6.37) 0.04
OR, odds ratio; CI, confidence interval; CAD, coronary artery disease; MI,
myocardial infarction; ACS, acute coronary syndrome; LVEF, left ventricular
ejection fraction.
Coronary CTA and MPI to detect flow-limiting stenoses 2927
coronary revascularization as a method to help providers more
fully incorporate clinical evidence into their decision-making
process. Additionally, a comprehensive non-invasive assessment
of CAD with CTA and MPI would allow for careful selection of
the optimal revascularization procedure according to the guide-
lines improving the balance between periprocedural risk and prog-
nostic benefit for each individual patient.
Study limitations
An important drawback of non-invasive cardiac imaging is the high
radiation exposure associated with CTA and MPI. In fact, studies
with 64-slice CTA reported an estimated radiation burden of up
to 21.4 mSv without the use of ECG-pulsing30 and MPI-SPECT
studies with 99mTc-based radiotracers are associated with radiation
doses in the range of 9–11 mSv.31 However, with the implemen-
tation of prospective ECG-gating protocols for CTA, radiation
exposure can be reduced down to 2.1 mSv32,33 and alternative
MPI techniques such as positron emission tomography with
13N-ammonia or 15O-water may reduce radiation placing the
resulting radiation exposure well within the range of conventional
CA. Additionally, hybrid imaging combining CTA using prospective
ECG gating with stress-only SPECT has been suggested as an
attractive alternative to standard stress/rest SPECT for the detec-
tion of CAD reducing radiation exposure to 5.4 mSv.34
In the present study, we have defined flow-limiting stenoses as
angiographically determined coronary narrowings associated with
a reversible perfusion defect in the subtended myocardial territory.
The perfusion defect was assessed by SPECT MPI, a method which
may be limited to accurately localize ischaemia-producing lesions in
patients with multivessel CAD.35 Thus, in these patients, determin-
ing which lesions warrant stenting can be difficult. This may poten-
tially be overcome by invasively assessed fractional flow reserve.24
Whether alternative measures such as, for instance, cardiac mag-
netic resonance imaging with an in-plane resolution superior to
SPECT may help solving this issue, remains to be determined.
Another shortcoming of our study was the limited number of
study participants. As a result, no significant increments in diagnos-
tic accuracy with CTA/MPI compared with MPI alone were
observed. Furthermore, it was not possible to perform subgroup
analysis across different patient strata such as patients with multi-
vessel vs. patients with single vessel disease. In addition, the
study was not designed to assess the clinical follow up. Therefore,
a potential improvement in clinical symptomatology justifying the
revascularization was possibly missed.
Conclusions
The combined non-invasive approach with CTA and MPI in
patients with known or suspected CAD has an excellent accuracy
to detect flow-limiting coronary stenoses compared with the gold
standard of QCA combined with MPI and may be used as a gate-
keeper for CA and revascularization procedures.
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